Novavax to present at the Stephens Nanotechnology conference


Mar 31, 2005, 00:00 ET from Novavax Inc.

    MALVERN, PA, March 29 /PRNewswire-FirstCall/ - Novavax, Inc., (Nasdaq:  
 NVAX) a specialty biopharmaceutical company, today announced that Dr. Rahul
 Singhvi, Vice-President Pharmaceutical Development and Manufacturing
 Operations, will be presenting at the Stephens Inc. 2005 Nanotechnology
 Investors Conference on Tuesday, April 5, 2005. Dr. Singhvi will provide an
 update on Novavax's novel micellar nanoparticle (MNP) technology and its
 potential for broad application.
     WHEN:  Tuesday, April 5th, 2005 at 10:30 AM PST
     WHERE: Ritz Carlton Hotel, 1401 South Oak Knoll Ave, Pasadena, California
     HOW:   The live broadcast of the presentation can be accessed through our
            website at After the presentation date, the
            webcast will be archived on our website for 90 days.
     Rahul Singhvi, Sc.D.
     Dr. Singhvi holds a Master and Doctorate of Science degree in Chemical
 Engineering from MIT and a Master of Business Administration from the Wharton
 School. Dr. Singhvi joined Novavax after 10 years experience with Merck & Co,
 where he most recently served as a Director within the Merck Manufacturing
     About Novavax Inc.
     Novavax, Inc. is a specialty biopharmaceutical company engaged in the
 research, development and commercialization of proprietary products focused on
 drug delivery and vaccine development. Novavax sells, markets, and distributes
 a line of women's health prescription pharmaceuticals through its specialty
 sales force calling on obstetricians and gynecologists throughout the United
 States including ESTRASORB(R), its topical emulsion for estrogen therapy.
 Novavax's micellar nanoparticle technology involves the use of patented oil
 and water nanoemulsions that it believes can be used as vehicles for the
 topical delivery of a wide variety of drugs and other therapeutic products,
 including hormones. In addition, Novavax conducts research and development on
 preventative and therapeutic vaccines and proteins for a variety of infectious
 diseases, including HIV, influenza, SARS and E-selectin tolerogen for the
 prevention of stroke.
     Statements made in this press release that state Novavax's or
 management's intentions, hopes, beliefs, expectations, or predictions of the
 future are forward-looking statements. Forward-looking statements include but
 are not limited to statements regarding product sales, future product
 development and related clinical trials and statements regarding future
 research and development. Novavax's actual results could differ materially
 from those projected in such forward-looking statements. Factors that could
 cause actual results to differ materially from those in the forward-looking
 statements include, among other things, the following: general economic and
 business conditions; competition; unexpected changes in technologies and
 technological advances; ability to commercialize and manufacture products;
 results of clinical studies; research and development activities; changes in,
 or failure to comply with, governmental regulations; and the ability to obtain
 adequate financing in the future. Additional information is contained in
 Novavax's annual report on Form 10K for the year ended December 31, 2004
 incorporated herein by reference. Statements made herein should be read in
 conjunction with Novavax's Form 10K. Copies of the filing may be obtained by
 contacting Novavax at 508 Lapp Road, Malvern, PA 19355 Tel 484-913-1200 or the
 SEC at

SOURCE Novavax Inc.